← Back to Clinical Trials
Recruiting NCT05697861
NCT05697861 Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT05697861 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Intellia Therapeutics |
| Condition | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 72 participants |
| Start Date | 2023-07-10 |
| Primary Completion | 2038-03 |
Trial Parameters
Condition Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Sponsor Intellia Therapeutics
Study Type OBSERVATIONAL
Phase N/A
Enrollment 72
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-07-10
Completion 2038-03
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Eligibility Criteria
Inclusion Criteria: 1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received. 2. A subject has provided informed consent for the LTFU study. Exclusion Criteria: None
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology